DOI: https://doi.org/10.53350/pjmhs22166178

ORIGINAL ARTICLE

Meta-Analysis of Safety Effect of Nitric Oxide Drugs on Acute Cerebral Hemorrhage

AKMAL ZUBAIR[1], WAJAHAT NADEEM[2], SUFIAN RASHEED[3], TANIA NAVEEL[4], SAMEEN FATIMA[5], MA. SOCORRO GONZAGA-LEONG-ON[6], MARIA BINTE SARFRAZ[7], NARGIS SARDAR[8], BAKHT BELAND[9], ARSALAN RASHEED[10*]

[1]*Department of Biochemistry, Quaid–I-Azam University Islamabad, Pakistan*
[2]*Dr.Panjwani Center for Molecular Medicine, International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi*
[3]*HEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences (ICCBS), University of Karachi, Karachi, Pakistan*
[4]*Department of Pharmacology, Jinnah University for Women, Karachi, Pakistan*
[5]*Department of Allied Health Sciences, Bakhtawar Amin Medical and Dental College, Multan, Pakistan*
[6]*College of Health and Allied Sciences, University of San Agustin, Iloilo City, Philippines*
[7]*Department of Physiology, Army Medical College, National University of Medical Sciences, Rawalpindi, Pakistan*
[8]*Department of Material Science and Electrical Engineering, State Research Institute, Center for Physical Sciences and Technology Vilnius, Lithuania*
[9]*Department of Biological Sciences, International Islamic University, Islamabad, Pakistan*
[10]*SST (Bio-Chemistry), Department of Elementary & Secondary Education, Pakistan*
Correspondence to Dr. Arsalan Rasheed, E-mail: arsalanrrasheed@gmail.com

ABSTRACT

Background: Nitric Oxide is involved in several physiological processes, including vasodilation, blood pressure control, platelet and antileucocyte activity, and neurotoxicity. When given within 4 to 6 hours after the start of stroke, nitric oxide donors (NO donors) have shown promise as an acute stroke therapy in two clinical studies.
Methods: People with acute or chronic stroke were included in randomized trials of NO donors, and IPD was obtained from the trialists. The changed Rankin scale (mRS) and mortality by point in time to randomization were used to evaluate the impact of NO donor organize on practical result. Impairment, mood, and life quality were all included as secondary outcomes.
Results: Glyceryl trinitrate (GTN) was used in all five studies (4,197 individuals). GTN reduced BP by 7.4/3.3mmHg as compare to the organize set. After 90 days, GTN has not altered any clinical measurements in any way, shape, or form. While GTN was linked with positive changes in the mRS (odds ratio (OR) of 0.52, 95% self-assurance gap of 0.34–0.78) and decreased mortality in 312 patients who were randomly assigned within 6 hours of the start of stroke, this was not the case for the other patients in the study.
Conclusions: Little donors had no effect on the recovery of stroke victims. NO donors, on the other hand, may enhance outcomes in both ischemic and hemorrhagic stroke when specified in six hours of the start of stroke.
Keywords: drugs, nitric oxide, Glyceryl trinitrate, acute cerebral hemorrhage, stroke, pharmacology

INTRODUCTION

When it comes to acute ischemic stroke, therapeutic options include intravenous thrombolysis, stroke unit care with moderate effectiveness but broad applicability, thrombectomy, and hemicraniectomy. However, despite their high effectiveness, these alternatives have a restricted marketability. No specific treatments exist for those who have spontaneous intracerebral haemorrhage despite the fact that lowering blood pressure regulation, platelet and antileucocyte action, and neurotoxicity are only a few of the numerous (BP) early on might be helpful and are optional in guiding principle (ICH). Novel therapies to improve results after an ischemic and hemorrhagic stroke are thus urgently required.

Vasodilation, BP regulation, platelet and antileucocyte action, and neurotoxicity are only a few of the numerous roles of nitric oxide in human physiology. Nitrogen dioxide (NO2) is a non-organic gas. If you've had an acute stroke, the amount of circulating NO is low, therefore early supplementation may assist restore equilibrium by lowering blood pressure, avoiding microthrombosis and decreasing leukocyte adhesion while also acting as an anti-inflammatory and therapeutic agent for the brain. In stroke animal models, NO donors have been studied for their therapeutic benefits, which are time-dependent. Because of its physiological property and possible advantages in stroke models in animals, NO usage may be beneficial for acute stroke patients.

Stroke survivors who had had an early or severe stroke were tested for the efficacy of two distinct NO donors. Blood pressure and platelet function were reduced in an uncontrolled study using potassium nitroprusside, a naturally produced NO donor, but cerebral blood flow was unaffected (CBF). Most study has been done on the synthetic nitrate used to treat angina known as glyceryl trinitrate (GTN). For acute stroke patients, we performed a thorough evaluation of data from randomised prohibited trials to review the protection and effectiveness of NO donors. Our hypothesis was that early administration of NO donors (defined as randomization in 6 hours of onset) might be particularly efficient in humanizing medical result because early administration of NO donors has been shown to be beneficial in preclinical study, a little medical experiment and a pre-specified subgroup of a larger test.

Received on 17-10-2021
Accepted on 25-05-2022

RESEARCH METHODOLOGY

Ethics: Since the anonymized patient data was obtained from previously completed and published research that had already acquired local and national clearances and authorization, this research did not require ethics committee clearance.
Collection Criteria and Search plan: Adult patients with acute or sub-acute stroke (ischaemic stroke or ischemic heart disease, within 1 week/168 hours of onset) were required by means of digital database searches such as the Cochrane Stroke Group Tests record (search October 2014), Cochrane Database of methodical Reviews (CDSR), and the Cochrane Central Register of prohibited trial (CENT). These trials were randomised controlled trials that looked at the outcome of a NO giver vs manage (placebo or lack of each database has its own search strategy (supplemental search criteria). For additional investigations, researchers combed through reference lists from previous evaluations of NO givers and BP-lowering medications and found test papers. Data from the original report was utilized in place of duplicate publications, which were found. Publications may be written in any language that is spoken in a given country.
Outcomes: Afterwards, students were asked to complete a modified Rankin scale (mRS) to assess their level of dependency on mRS. There was also evaluation of hemodynamics during randomization, such as changes in blood pressure and heart rate as well as recurrence, disability, and headache as well as clinically significant hypertension based on the Scandinavian Stroke Score (SSS). The length of stay in hospital and the patient's post-discharge status were included into the analysis. During the follow-up period, researchers assessed participants' functional position (e.g. Barthel index, BI), mental health, cognition, and mood (e.g. mini-mental state assessment, MMSE), as well as their overall well-being (e.g. EuroQoL-5D, EQ-5D; EuroQol-Visual Analogue Scale, EQ-VAS) (e.g., Zung depression scale, ZDS). The safety precautions included provisions for fatalities and other catastrophic outcomes (SAEs).
Data: Data from complete trial was requested from each one main researcher, and it was given to them digitally (e.g., in Excel, SAS, or SPSS format). Among the baseline factors covered by the study's data were demographic trends, blood vessel risk factors, hemodynamics, stroke type (ischemic stroke; ICH), stroke severity (e.g. Scandinavian Stroke Scale, SSS), time from initiation to randomization (OTR, as a surrogate for time to treatment), and use of clot dissolving methods and results.

The Validity of the Trial: The excellence of clinical trials was assessing by the Cochrane Collaborative Criteria, which took into account factors such as randomization method, allocation concealment, blinding therapy administration, and blinded outcome assessment, among others. The risk assessment was confidential as "low risk," "high risk," or "unclear risk" according to the Johnson Handbook for Meta Analyses of intervention. Statistics: TICS-M 1, tMMSE 1, HUS 0, and ZDS 102.5 were employed as the extremes for death in the experiments. An NO donor's impact on future occurrences or outcomes is described using probability values (OR) or mean differences (MD) and 95% confidence periods. Statistics models included for time to randomization, age, gender and the type of stroke (ischaemic or hemorrhagic), stroke severity, stroke syndrome and systolic blood pressure in order to account for these factors Patients with a history of high blood pressure, stroke, or stroke intensity (SSS > 35, 35) were divided into subgroups based on the following baseline characteristics: age (70 years, sex; IS; ICH); a history of high blood pressure or stroke; stroke severity (SSS > 35; 35); systolic blood pressure (170 mmHg; SSS > 35; 35); and time from stroke to randomization (3, 3 hours); Using an OLR model modified to include an interaction term, we ran a subgroup analysis. Data may be described using words like quantity (percentage), average (interquartile range), or average (range of error). The studies were performed using SAS 9.3 and the findings are impressive.

RESULTS

I**ncluded Trials:** There were eight clinical trials that used nitric oxide donors to treat acute stroke patients. Three studies were ruled out: a finished hospital-based sodium nitroprusside uncontrolled trial, a prehospital ambulance-based phase I GTN uncontrolled study now underway, and a prehospital ambulance-based phase III GTN randomised controlled research currently underway. The five research considered were all randomised control trials that looked at GTN levels in acute stroke patients. Phase II investigations were conducted in four modest single-center trials whereas ENOS included 4011 participants from 173 locations in 23 countries (Supplemental Table I). An experiment in which paramedics recruited patients from the community and enrolled them and got their permission and started them on treatment; four additional experiments in which stroke patients were recruited from care facility stroke services throughout the acute and subacute time following stroke. After randomization to GTN/control in the Rescue van study and earlier than randomization in the big hospital test, intravenous thrombolysis was delivered. One study was prospective study, one was placebo-controlled, and the other three were single-blind. GTN was given as a transdermal patch at a dose of 5 mg daily in all five studies; one trial also tested the dose at 10 mg for each day in a subgroup of 20 patients. Along with design variations, the studies varied in terms of patient variables such as age, sex distribution, health information (high blood pressure, diabetes mellitus), systolic, stroke intensity, and the kind of alteplase used (Table 1).

Table 1. Demography of the patients



Excellence of the Evidence: Supplemental Table 1 shows that the included studies had a high level of quality in general. Each research made a point of disclosing the randomization method they used. There were specifics on how much blood pressure was recorded, how many measurements were taken, and what equipment was utilized. The results of each trial were not influenced equally by all of the experiments that took place. According to the study papers, outcome evaluation was performed in a blinded fashion (and protocols when available). All participants were found, and only a small number of patients were missed throughout the investigation.

Enroll Patients: The studies included a total of 4197 individuals, of whom 2113 were randomly assigned to receive GTN and 2084 received no GTN at all (Table 1). The average lifetime was 70.4 (12.1%) years, with a standard deviation of 12.1. Of the 2383 participants, 56.8% were male. 2700(64.3%) of patients had a history of hypertension, whereas 623(15%) had a history of stroke, and 686 (16.5%) had a history of IHD. There were 3976 (94.7%) patients with high BP at baseline, with an average BP of 167.1 (19.3)/89.5 (13.3) mmHg (systolic BP more than 140 mmHg). Patients with an ischaemic stroke comprised 3502 (83.4 percent) of the total; those with an ICH comprised 646 (15.4%). Stroke patients were randomly assigned within six hours after ictus on average (27.2 (16.1) hours after the start of symptoms. Time to randomization for quite a few baseline character varied amongst patients' characteristics, including sex, history of high blood pressure and decreased perfusion heart disease, stroke intensity (Scandinavian Stroke Scale), systolic and diastolic blood pressure, heart rate, and dealing with alteplase (Supplemental Table II). Patients who were randomly assigned during the first six hours had a lower incidence of diabetes and a higher incidence of high blood pressure (systolic BP > 140 mmHg), presentation with an ICH, and receipt of rt-PA than those who were assigned later (if qualify occasion was an ischaemic stroke).

Clinical Outcomes: Blood force decreased by 7.4/3.3mmHg on average after the first treatment with GTN as opposed to not using GTN; nevertheless, heart count rose by 1.9bpm while using GTN (Table 2). A higher incidence of pain (369/2033, 18.2% vs 171/2026, 8.4%) and clinical decreased blood pressure (i.e., hypotension needing checkup interference, 55/2033, 2.7%) was seen with GTN. It did not make a difference in the rates of mortality or worsening or severe negative events at the conclusion of the randomised therapy of 7 to 12 days. No changes were seen in the mortality or institutionalization rates or duration of stay after hospital release (Table 2).

Table 2: Clinical outcomes of the patients



Measures such as mortality, dependency (mRS), disability, cognitive (MMSE, TICS, and linguistic naming), mood (ZDS), or life quality revealed no changes among GTN and no GTN by day 90, regardless of whether they were based on genetic testing or not (EQ-5D as HUS, EQ-VAS). When examined in predefined subcategories with duration to treatment interaction, patients receiving with GTN within 6 hours had a higher mRS score (see Figure 1 for an illustration). This therapy also has a sex impact (with efficacy only shown in females). There was no correlation between age, cardiovascular diseases, type of stroke, intensity of stroke, systolic BP and time between start to randomization.

Outcomes by Time from Stroke to Randomisation: No impact was seen after 5–10 hours and for up to 50 hours in the analysis of the mRS by time to randomisation, although earlier treatment seemed to be effective (shift in the mRS) (Fig. 2). Three hundred and twelve stroke patients were randomly assigned to one of five treatment groups within six hours of their symptoms beginning (ENOS, RIGHT). Death (lower mRS ratings) and dependence (higher Barthel index scores)

decreased significantly, as did the number of patients with depressed mood (lower ZDS scores) and cognitive impairment (higher tMMSE and TICS scores) in patients randomly assigned to GTN within six hours at 90 days (Table 2).

Figure 1. Forest plot showing the analysis of duration to treatment interaction



Figure 2. Analysis of the mRS by time to randomization.



Figure.3



In predefined subgroups, there were no treatment/mRS interactions found. Men are more likely to benefit than women on average (and this is true throughout all studies and recruiting periods), which suggests that the trend is due to chance. Both haemorrhagic and ischemic stroke patients had significant reductions in mortality or dependence when treated with GTN (Figure 4). Patients who got combined GTN and thrombolysis for an ischemic stroke had a substantial decrease in mortality or reliance. Patients who had an ischemic stroke and did not undergo thrombolysis did not benefit although a tendency in favour of GTN treatment was observed in a post-hoc, unadjusted, Mann-Whitney test comparison.

Beyond 6 hours of GTN use vs no GTN use, there was no indication of advantage or harm overall. Patients randomly assigned to GTN after 48 hours had worse cognitive scores (Table 2). The moment effects of GTN were seen in individuals randomised within 6 hours of the start for mRS, BI, EQ-5D, EW-VAS, ZDS and mortality when evaluating the continuous connection among result and time to randomisation (Figure 4).

Figure 4. Evaluation of the continuous connection among result (moment effects of GTN were seen in individuals randomised within 6 hours) and time to randomisation



DISCUSSION

Acute stroke patients should not be treated with organs from donors who have never had a stroke. 4197 individuals with acute ischemic stroke (ICH) were evaluated in five randomized trials for the organic nitrate GTN. There was no difference in functional result, disability, cognition, mood, or overall health when GTN was used. GTN was shown to have a superior result at day 90 in patients who were randomly assigned to it within six hours of the start of their stroke, a predetermined subset.

Many factors indicate that even if the apparent advantage observed in patients who were randomly assigned during the previous 6 hours was due to chance, the result may be genuine. First, in two separate trial datasets, early delivery of GTN was shown to have positive effects on mRS, with odds ratios of 0.08 (95% CI 0.02–0.41) for the RIGHT group and 0.57 (95% CI 0.37–0.89) for the ENOS group given within 6 hours (median time 258 minutes). First and foremost, a study of over 300 patients showed that the treatment had an impact. A third finding showed that an impact was time-dependent, with the most benefit occurring in individuals who were treated early in the 6-hour time period. Fourteenth, there was a favourable correlation between the interventions and a range of outcomes such as decreased mortality, decreased dependence and handicap, as well as improved cognition and mood. Fifth, early therapy had an impact on all predetermined subcategories and was unaffected by stroke type, intensity, or baseline blood pressure levels. Lastly, a meta-analysis of prior to clinical stroke studies using NO donors found a time-dependent neuroprotective impact, with trials treating donors within 60 minutes of ischaemia initiating being favourable and those with a greater time frame (up to 48 hours) is being neutral.

Hyperacute GTN administration may help stroke patients in many ways if it is shown to be effective. These steps, when taken simultaneously, may be able to "buy time," preserve the brain, and make patients who have had an ischemic stroke ready for thrombolysis treatment. As a result, rapid supplementation may help repair this local deficit. NO/GTN reduces blood pressure in acute/subacute stroke, which may help high blood pressure patients progress down the "J-shaped" epidemiological curve that links high blood pressure to a poor functional result. Lowering blood pressure may help prevent recurrence and haematoma growth after an ischemic stroke. Ischaemic stroke has extra processes that don't apply to other types of stroke. The second reason is that NO dilates cortical arteries (such as those in the middle cerebral hemisphere), which may enhance individual firm perfusion (via the "front door") without stealing from other parts of the brain, as shown in the GTN-3 pilot experiment. Third, NO has been proven experimentally to be a strong dilator of the pial arteries and may thus enhance organ perfusion via the "backdoor" secuirty system.

Numerous advantages may be found in this investigation. Prior controlled studies with NO donors are used to identify specific patients. Since individual patient data meta-analyses allow for covariate adjusted analyses (and thus may correct any nonmajor imbalances at baseline), they are regarded as the "gold standard". There are also over 4000 participants in the study, making it similar to a meta-regression analysis of thrombolytic' impact on time to randomization. Last but not least, it examines the effectiveness and safety of the treatment across a range of physical and mental outcomes; the findings are consistent across all of the study's outcomes, demonstrating internal consistency.

There are however a few drawbacks to be aware of. This study only looked at GTN, thus the findings may not be generalizable to other nitric oxide providers. However, the inclusion of the four pilot trials widens the time frame under consideration in the analyses; RIGHT investigated ultra-acute prehospital care (4 hours with a median duration of 55 minutes), while the three previous pilot studies looked at

times longer than 48 hours. To add another wrinkle, only one of the trials was double-masked (due to the lack of commercially available placebo GTN patches starting in the late 1990s); although each test employed one or more self-reliant analyzers blinded to diagnosis to record clinical results, spectator bias could be ruled out). GTN may also induce headache, which may have blinded some sufferers to their therapy. The findings are from a single research group, and it is critical that additional research organizations look into the function of GTN in the early stages of stroke before drawing any conclusions. Finally, only two of the five studies included patients who were treated within six hours after the start of their stroke. It's important to note that the findings from this pre-specified subset are still preliminary and indicate the necessity for larger multicenter studies including stroke patients who are in the most acute stage of recovery. 850 patients enlisted by paramedics in the prehospital environment are participating in the RIGHT-2 study, which is evaluating GTN for this indication. Other prehospital studies are being planned. Prehospital care may also reduce the number of hospital-based interventions needed and their effectiveness. There was an increase in the use of thrombolysis in the RIGHT trial, but reduced neurovascular damage from GTN therapy may decrease the require for other intervention such as within major therapy or interventions.

CONCLUSION

In stroke patients with acute or subacute symptoms, the chances of survival aren't increased by donating NO or GTN. Acute myocardial infarction treated patients with nitrates had similar results. Good results in a small group of patients who were randomly allocated within six hours warrant additional revision, in particular as GTN is widely obtainable, cheap, and simple to control in the prehospital location preceding to mind imaging and may be given in this manner.

Disclaimer: None.
Competing interest: No competing and challenging interest
Source of funding: None

REFERENCES

1. J. Emberson, K. R. Lees, P. Lyden et al., “Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials,” The Lancet, vol. 384, no. 9958, pp. 1929–1935, 2014.
2. J. M. Wardlaw, V. Murray, E. Berge, and G. J. del Zoppo, “Thrombolysis for acute ischaemic stroke,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD000213, 2009.View at: Google Scholar
3. O. A. Berkhemer, P. S. S. Fransen, D. Beumer et al., “A randomized trial of intraarterial treatment for acute ischemic stroke,” The New England Journal of Medicine, vol. 372, no. 1, pp. 11–20, 2015.View at: Publisher Site
4. B. C. V. Campbell, P. J. Mitchell, T. J. Kleinig et al., “Endovascular therapy for ischemic stroke with perfusion-imaging selection,” The New England Journal of Medicine, vol. 372, no. 11, pp. 1109–1018, 2015.View at: Publisher Site
5. M. Goyal, A. M. Demchuk, B. K. Menon et al., “Randomized assessment of rapid endovascular treatment of ischemic stroke,” The New England Journal of Medicine, vol. 372, no. 11, pp. 1019–1030, 2015.View at: Publisher Site
6. K. Vahedi, J. Hofmeijer, E. Juettler et al., “Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials,” The Lancet Neurology, vol. 6, no. 3, pp. 215–222, 2007.View at: Publisher Site | Google Scholar
7. P. A. G. Sandercock, C. Counsell, G. J. Gubitz, and M.-C. Tseng, “Antiplatelet therapy for acute ischaemic stroke,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD000029, 2008.View at: Google Scholar
8. Stroke Unit Trialists' Collaboration, “Organised inpatient (stroke unit) care for stroke,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD000197, 2007.View at: Publisher Site | Google Scholar
9. C. S. Anderson, E. Heeley, Y. Huang et al., “Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage,” The New England Journal of Medicine, vol. 368, no. 25, pp. 2355–2365, 2013.View at: Publisher Site J. C. Hemphill, S. M. Greenberg, C. S. Anderson et al., “Guidelines for the management of spontaneous intracerebral hemorrhage,” Stroke, vol. 46, no. 7, pp. 2032–2060, 2015.View at: Publisher Site | Google Scholar
10. R. M. J. Palmer, A. G. Ferrige, and S. Moncada, “Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor,” Nature, vol. 327, no. 6122, pp. 524–526, 1987.View at: Google Scholar
11. M. W. Radomski, R. M. J. Palmer, and S. Moncada, “The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium,” Biochemical and Biophysical Research Communications, vol. 148, no. 3, pp. 1482–1489, 1987.
12. R. G. Knowles, M. Palacios, R. M. J. Palmer, and S. Moncada, “Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase,” Proceedings of the National Academy of Sciences of USA, vol. 86(13):5159–5162, 1989.
13. D. D. Rees, R. M. J. Palmer, and S. Moncada, “Role of endothelium-derived nitric oxide in the regulation of blood pressure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 9, pp. 3375–3378, 1989.View at: Google Scholar
14. S. Ferlito, M. Gallina, G. M. Pitari, and A. Bianchi, “Nitric oxide plasma levels in patients with chronic and acute cerebrovascular disorders,” Panminerva Medica, vol. 40, no. 1, pp. 51–54, 1998.View at: Google Scholar
15. P. A. Rashid, A. Whitehurst, N. Lawson, and P. M. W. Bath, “Plasma nitric oxide (nitrate/nitrite) levels in acute stroke and their relationship with severity and outcome,” Journal of Stroke and Cerebrovascular Diseases, vol. 12, no. 2, pp. 82–87, 2003.View at: Google Scholar
16. M. Willmot, L. Gray, C. Gibson, S. Murphy, and P. M. W. Bath, “A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow,” Nitric Oxide—Biology and Chemistry, vol. 12, no. 3, pp. 141–149, 2005.View at: Google Scholar
17. P. S. Garry, M. Ezra, M. J. Rowland, J. Westbrook, and K. T. S. Pattinson, “The role of the nitric oxide pathway in brain injury and its treatment—from bench to bedside,” Experimental Neurology, vol. 263, pp. 235–243, 2015.
18. R. J. Butterworth, A. Cluckie, S. H. D. Jackson, M. Buxton-Thomas, and P. M. W. Bath, “Pathophysiological assessment of nitric oxide (given as sodium nitroprusside) in acute ischaemic stroke,” Cerebrovascular Diseases, vol. 8, no. 3, pp. 158–165, 1998.View at: Google Scholar
19. S. Ankolekar, M. Fuller, I. Cross et al., “Feasibility of an ambulance-based stroke trial, and safety of glyceryl trinitrate in ultra-acute stroke: the rapid intervention with glyceryl trinitrate in hypertensive stroke trial (RIGHT, ISRCTN66434824),” Stroke, vol. 44, no. 11, pp. 3120–3128, 2013.View at: Google Scholar
20. P. M. W. Bath, L. Woodhouse, P. Scutt et al., “Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial,” The Lancet, vol. 385, no. 9968, pp. 617–628, 2015.View at: Google Scholar
21. C. Geeganage and P. M. Bath, “Vasoactive drugs for acute stroke,” Cochrane Database of Systematic Reviews, vol. 7, Article ID CD002839, 2010.
22. J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, The Cochrane Collaboration, 2011.
23. J. Bamford, P. Sandercock, M. Dennis, J. Burn, and C. Warlow, “Classification and natural history of clinically identifiable subtypes of cerebral infarction,” The Lancet, vol. 337, no. 8756, pp. 1521–1526, 1991.View at: Google Scholar
24. P. M. W. Bath, R. Pathansali, R. Iddenden, and F. J. Bath, “The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke,” Cerebrovascular Diseases, vol. 11(3): 265–272, 2001.
25. P. Rashid, C. Weaver, J. Leonardi-Bee, F. Bath, S. Fletcher, and P. Bath, “The effects of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure, cerebral and cardiac hemodynamics, and plasma nitric oxide levels in acute stroke,” *Journal of Stroke and Cerebrovascular Diseases*, vol. 12, no. 3, pp. 143–151, 2003.View at: Publisher Site | Google Scholar
26. M. Willmot, A. Ghadami, B. Whysall, W. Clarke, J. Wardlaw, and P. M. W. Bath, “Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke,” *Hypertension*, vol. 47, no. 6, pp. 1209–1215, 2006.View at: Publisher Site | Google Scholar
27. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, “Tissue plasminogen activator for acute ischemic stroke,” *The New England Journal of Medicine*, vol. 333(24):1581–1587, 1995.
28. J. Leonardi-Bee, P. M. W. Bath, S. J. Phillips, and P. A. G. Sandercock, “Blood pressure and clinical outcomes in the International Stroke Trial,” *Stroke*, vol. 33, no. 5, pp. 1315–1320, 2002.View at: Publisher Site | Google Scholar
29. C. S. Anderson, Y. Huang, J. G. Wang et al. et al., “Intensive blood pressure reduction in actue cerebral haemorrhage trial (interact): a randomised pilot trial,” *Lancet Neurology*, vol. 7(5+: 391–399, 2008.
30. E. Morikawa, S. Rosenblatt, and M. A. Moskowitz, “L-arginine dilates rat pial arterioles by nitric oxide-dependent mechanisms and increases blood flow during focal cerebral ischaemia,” *British Journal of Pharmacology*, vol. 107, no. 4, pp. 905–907, 1992.View at: Publisher Site | Google Scholar
31. F. Zhang, J. G. White, and C. Iadecola, “Nitric oxide donors increase blood flow and reduce brain damage in focal ischemia: evidence that nitric oxide is beneficial in the early stages of cerebral ischemia,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 14, no. 2, pp. 217–226, 1994.View at:
32. J. B. Salom, M. Ortí, J. M. Centeno, G. Torregrosa, and E. Alborch, “Reduction of infarct size by the NO donors sodium nitroprusside and spermine/NO after transient focal cerebral ischemia in rats,” *Brain Research*, vol. 865, no. 2, pp. 149–156, 2000.View at: Publisher Site | Google Scholar
33. M. Khan, M. Jatana, C. Elango, A. Singh Paintlia, A. K. Singh, and I. Singh, “Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke,” *Nitric Oxide*, vol. 15, no. 2, pp. 114–124, 2006.View at: Publisher Site | Google Scholar
34. P. Zhuang, H. Ji, Y.-H. Zhang, Z.-L. Min, Q.-G. Ni, and R. You, “ZJM-289, a novel nitric oxide donor, alleviates the cerebral ischaemic–reperfusion injury in rats,” *Clinical and Experimental Pharmacology and Physiology*, vol. 37, no. 3, pp. e121–e127, 2010.View at: Publisher Site | Google Scholar
35. M. J. Clarke and L. A. Stewart, “Systematic Reviews: Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses?” *British Medical Journal*, vol. 309, pp. 1007–1010, 1994.
36. K. R. Lees, E. Bluhmki, R. von Kummer et al., “Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials,” *The Lancet*, vol. 375, no. 9727, pp. 1695–1703, 2010.View at: Publisher Site | Google Scholar
37. H. M. den Hertog, H. B. van der Worp, H. M. A. van Gemert et al., “The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial,” *The Lancet Neurology*, vol. 8, no. 5, pp. 434–440, 2009.View at: Publisher Site | Google Scholar
38. K. D. Hougaard, N. Hjort, D. Zeidler et al., “Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial,” *Stroke*, vol. 45, no. 1, pp. 159–167, 2014.
39. L. Woodhouse, P. Scutt, K. Krishnan et al., “Effect of hyperacute administration (within 6 hours) of transdermal glyceryl trinitrate, a nitric oxide donor, on outcome after stroke: subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial,” *Stroke*, vol. 46, pp. 3194–3201, 2015.